Founded in 2003, AngioScore is a privately held company backed by several venture capital firms. The AngioSculpt Scoring Balloon Catheter received the CE Mark for use in the coronary arteries in September 2004. The CE Mark for use in the peripheral arteries was granted in May 2005. Outside of the US, we currently have distribution in over 10 EU countries, as well as several in Scandinavia and the Asia/Pacific region. AngioScore Inc. develops, manufactures and markets the AngioSculpt Scoring Balloon Catheter for both the coronary and peripheral interventional markets. These markets represent a worldwide opportunity of over $2 billion. Designed specifically to address the limitations of conventional angioplasty balloon catheters, AngioSculpt combines a semi-compliant balloon with an innovative nitinol scoring element.
